1 October 2025
For the fourth year in a row, the Medicines Patent Pool (MPP) has been recognised as a High Performer in the 2025 Global Health 50/50 Report: Holding the Line. At a time when commitments to gender equality are slipping across the global health sector, MPP is strengthening ours. Our continued strong performance reflects our unwavering commitment to fairness, equity and inclusion — principles rooted in the realities of the communities we serve.
Click here to access the full report
In 2024, MPP adopted a new Menstrual and Menopause Policy, offering flexible work arrangements, awareness-raising, and training to better support women’s health needs. We are pleased to see this initiative featured in the report, recognising it as an important step forward for equity in the workplace.
This policy is part of MPP’s broader approach to ensure our staff feel supported and empowered to thrive at all stages of their professional and personal lives.
Being recognised as a High Performer is not the finish line. MPP will continue to strengthen workplace equity and inclusion policies, monitor progress through data and transparency, champion diversity in leadership and governance and ensure our values are reflected in how we serve people worldwide.
Read the 2025 Global Health 50/50 Report: Holding the Line
Download MPP’s full report
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.